Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67,895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Avet-Loiseau H, et al. Among authors: wang m. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20. Blood. 2016. PMID: 27439911 Free PMC article. Clinical Trial.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Weber DM, et al. Among authors: wang m. N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596. N Engl J Med. 2007. PMID: 18032763 Free article. Clinical Trial.
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Harousseau JL, et al. Among authors: wang m. Haematologica. 2010 Oct;95(10):1738-44. doi: 10.3324/haematol.2009.015917. Epub 2010 May 11. Haematologica. 2010. PMID: 20460639 Free PMC article.
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Jacobs RW, et al. Among authors: wang m. Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):36-42. doi: 10.1016/j.clml.2015.11.005. Epub 2015 Dec 1. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26702475
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Dimopoulos M, et al. Among authors: wang m. J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7. J Hematol Oncol. 2018. PMID: 29615082 Free PMC article. Clinical Trial.
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Qazilbash MH, et al. Among authors: wang m. Biol Blood Marrow Transplant. 2007 Sep;13(9):1066-72. doi: 10.1016/j.bbmt.2007.05.014. Epub 2007 Jul 16. Biol Blood Marrow Transplant. 2007. PMID: 17697969 Free article.
67,895 results
You have reached the last available page of results. Please see the User Guide for more information.